Myocardial infarction
MONDO:0005068Gross necrosis of the myocardium, as a result of interruption of the blood supply to the area, as in coronary thrombosis.
Also known as: MI, MI, myocardial infarction, heart attack, infarction (MI), myocardial, myocardial infarct, myocardial infarction, myocardial infarction (disease), myocardial infarction, (MI)
612 clinical trials for this condition and its sub-types, 369 tagged with Myocardial infarction itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Myocardial infarction
-
Acute myocardial infarction 200 trials · 369 incl. sub-types
6 sub-types
- ST-elevation myocardial infarction 221 trials
- Acute subendocardial myocardial infarction 32 trials
- Acute anterolateral myocardial infarction 2 trials
- Acute inferolateral myocardial infarction 0 trials
- Acute inferoposterior infarction 0 trials
- Strictly posterior acute myocardial infarction 0 trials
-
Subendocardial myocardial infarction 0 trials · 32 incl. sub-types
1 sub-type
-
Anterolateral myocardial infarction 11 trials
1 sub-type
-
Myocardial stunning 4 trials
-
Inferior myocardial infarction 2 trials
-
Silent myocardial infarction 2 trials
-
Anteroseptal myocardial infarction 0 trials
-
Apical myocardial infarction 0 trials
-
Inferolateral myocardial infarct 0 trials
-
Lateral myocardial infarction 0 trials
-
Posterior myocardial infarction 0 trials
-
Posterolateral myocardial infarction 0 trials
-
Septal myocardial infarction 0 trials
-
New drug aims to heal hearts after attack – but trial halted early
Disease control Stopped earlyThis study tested an experimental drug called BI 765845 in 160 adults who had just had a heart attack. Participants received either the drug or a placebo, and doctors measured heart damage using MRI scans over 3 months. The trial was terminated early, so it is unclear if the drug…
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Experimental blood thinner tested in heart attack emergency
Disease control Stopped earlyThis study tested an intravenous antiplatelet drug called PRT060128 in 70 people having a severe heart attack (STEMI). The goal was to see if giving the drug before emergency artery-opening treatment improved blood flow and was safe. The trial was terminated early, so the full re…
Phase 2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Heart attack drug trial halted early: Colchicine's nerve protection unproven
Disease control Stopped earlyThis study tested whether the anti-inflammatory drug colchicine could prevent nerve damage in the heart after a heart attack. About 54 adults who had a first heart attack and underwent artery-opening treatment were given colchicine or a placebo for one month. The trial was termin…
Phase 2/3 • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Less invasive heart attack care for the elderly put to the test
Disease control Stopped earlyThis study looked at two ways to manage older patients (80+) who had a mild type of heart attack (NSTEMI). One group got routine angiography (an invasive look at the heart's arteries), while the other group first had a non-invasive imaging test (SPECT or stress echo) and only got…
Sponsor: University Hospital, Grenoble • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Heart attack study halted: could conditioning the heart and arm help?
Disease control Stopped earlyThis study looked at whether using two types of 'ischemic conditioning' (brief cycles of blood flow restriction and release) could improve outcomes for people having a major heart attack. One method used a blood pressure cuff on the arm, the other used a balloon inside the heart …
Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Heart attack patients may get safer blood thinners tailored to their genes
Disease control Stopped earlyThis study tested whether personalizing blood-thinning drugs based on a patient's genetics and risk factors could reduce bleeding after a heart attack. It enrolled 39 patients who had already been on standard dual therapy for a year. The trial was terminated early, so the finding…
Phase 4 • Sponsor: Ottawa Heart Institute Research Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
One shot may replace hours of infusion for heart attack care
Disease control Stopped earlyThis study tested whether a single dose of the drug abciximab given directly into the heart artery works as well as the standard approach of a dose into a vein followed by a 12-hour infusion. The goal was to reduce heart muscle damage in people having their first non-ST elevation…
Phase 4 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New CT scan could replace multiple heart tests after attack
Diagnosis Stopped earlyThis study tested whether a special CT scan can accurately assess heart muscle damage in people who had a heart attack more than 24 hours earlier. The goal was to see if this CT could replace the need for both an MRI and an invasive angiogram. The study enrolled 31 adults and com…
Sponsor: University Hospital, Rouen • Aim: Diagnosis
Last updated Jun 27, 2026 12:08 UTC
-
Aged heart cells may hold clues to heart disease progression after attack
Knowledge-focused Stopped earlyThis study looks at whether heart cells that age rapidly after a heart attack release harmful proteins that make heart disease worse. Researchers will collect blood and heart tissue samples from people undergoing coronary artery bypass surgery after a recent heart attack or for s…
Sponsor: South Tees Hospitals NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC